Bionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002

Bionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002 Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics designed to harness multi-targeted biology for immune-mediated inflammatory…

Read MoreBionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002

Algia Pharma Reports Positive IND-Enabling Study Results for AlgiaPak® Non-Opioid Acute Pain Treatment

Algia Pharma Completes IND-Enabling Toxicology Study for AlgiaPak, Advancing Non-Opioid Acute Pain Treatment Toward Clinical Trials Algia Pharma, LLC has announced the successful completion of an Investigational New Drug (IND)-enabling…

Read MoreAlgia Pharma Reports Positive IND-Enabling Study Results for AlgiaPak® Non-Opioid Acute Pain Treatment

Orogen Therapeutics Selects Two Development Candidates for Immune Diseases, Targeting IL-17 and JAK1/TYK2

Orogen Therapeutics Selects ORO-110 and ORO-210 Development Candidates for Inflammatory Diseases Orogen Therapeutics, Inc. (“Orogen” or the “Company”) announced the selection of two development candidates, ORO-110 and ORO-210, as potential…

Read MoreOrogen Therapeutics Selects Two Development Candidates for Immune Diseases, Targeting IL-17 and JAK1/TYK2

Roquette Showcases Comprehensive Excipient Solutions and Technical Expertise at AAPS PharmSci 360 2026

Roquette to Showcase Advanced Pharmaceutical Excipients and Drug Delivery Innovations at AAPS PharmSci 360 2026 Roquette, a global leader in plant-based ingredients, pharmaceutical excipients and specialized pharmaceutical solutions, will present…

Read MoreRoquette Showcases Comprehensive Excipient Solutions and Technical Expertise at AAPS PharmSci 360 2026